Farzan Nima sold $28K of KROS
Farzan Nima sold 2,625 shares of Keros Therapeutics, Inc. (KROS) at $10.73 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing documents a director’s open-market sale executed under a pre-arranged 10b5-1 plan; it is more of a compliance/ownership update than a new business development.
Market read
Ownership-change filings can marginally influence sentiment, but this one is explicitly pre-arranged and relatively small in dollar terms.
What to watch
The article provides only the sale details; it does not indicate whether other insiders/10b5-1 plans are selling or buying around the same period.
Background
This is an SEC Form 4 insider transaction disclosure for Keros Therapeutics, Inc. (KROS).
Ticker impact
Director Farzan Nima sold 2,625 Keros Therapeutics shares for ~$28.2K under a pre-arranged 10b5-1 plan (Form 4).
Low near-term impact; any reaction likely fades unless accompanied by other news.
The disclosure is an open-market sale by a director with an explicit pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a small, pre-planned insider sale.
None.
None.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution; traders may watch for follow-on sales or changes in trading patterns.
Key entities
- issuerKeros Therapeutics, Inc.
Company whose shares were sold by a director under a 10b5-1 plan.
- insiderFarzan Nima
Director who sold 2,625 shares on June 4, 2026.